Phadia US Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.0M | 88 | 31.4% |
| Food and Beverage | $794,749 | 36,437 | 24.5% |
| Honoraria | $745,839 | 422 | 23.0% |
| Consulting Fee | $546,777 | 145 | 16.9% |
| Travel and Lodging | $128,640 | 197 | 4.0% |
| Education | $2,531 | 1 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,225 | 2 | 0.1% |
| Charitable Contribution | $1,000 | 1 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| CABAI 2104 Study Dynamics of SARS-CoV2 transmission and disease | $158,277 | 0 | 2 |
| Investigation of IgG4 and IgE Antibodies to the component proteins of Milk, Other Foods and inhalants associated with EoE | $125,880 | 0 | 2 |
| Development of IgG4 and IgE antibodies to food and food antigens during first 3 years of life in a random cohort | $122,376 | 0 | 2 |
| Diagnostic Performance of Boiled Milk IGE CAP in baked milk allergy in children | $97,218 | 0 | 2 |
| Investigating the Relevance of IgE to galactose (a-Gal) in coronary artery disease - CABAL 2015 CF | $61,459 | 0 | 1 |
| Improving Asthma Outcomes | $46,381 | 0 | 1 |
| Dietary Management of Adult and Childrens Eosinphilic Esophagitis: The Efficacy of dietary interventions | $45,641 | 0 | 5 |
| IDEA Investigating Duliumabs Effect on Asthma by Genotype- CABAL 1922 | $42,540 | 0 | 3 |
| Research Grant Agreement to determine the earliest risk factors for food allergy development. Evaluate sensitization to food allergens in children with FPIAP compared to healthy controls in the cohort | $40,087 | 0 | 3 |
| Dietary Management of Adult Eosinphilic Esophagitis: The Efficacy of dietary interventions | $39,287 | 0 | 8 |
| Controlling and Preventing Asthma Progression and Severity in kids with Omalizumab-Preventing Asthmas in High Risk Kids (PARK | $31,417 | 0 | 16 |
| Allergen Sensitization and Exposure Pilot | $30,640 | 0 | 2 |
| Use if Liklihood Ratios to Determine the Most Clinically and Cost Effective Predictor or Clinical Allergy | $25,000 | 0 | 1 |
| Duke Prestige Award Aeroallergen-sensitization and pulmunary function outcomes in children ith chronic respiratory disease | $25,000 | 0 | 1 |
| Advancing Understanding of the Diagnosis and Management of Childhood Allergy among Medicaid Enrolled Children | $19,890 | 0 | 1 |
| Inner City Asthma | $18,433 | 0 | 1 |
| Relevance of Der p23 to symptoms of asthma and rhinitis in an unselected birth cohort | $17,919 | 0 | 1 |
| Tryptase | $16,225 | 0 | 4 |
| Improving Technology-Assisted Recording of Asthma Control in Children | $11,693 | 0 | 10 |
| Family Member Screening for Celiac Disease | $11,519 | 0 | 2 |
| CABAL 1803 Allergen Specific Component Resolved Diagnostics and Atopic Progression Profiling in Context of Omalizumab Asthma Preventention Trial | $7,680 | 0 | 2 |
| Evaluation of the Phadia ImmunoCAP PR3, MPO and GBM | $6,912 | 0 | 1 |
| Testing the Efficacy of school based environmental intervention targeting pest allergens, mold and pollution | $4,874 | 0 | 2 |
| PARK CABAL 1803 Allergen Specific Component Resolved Diagnostics and Atopic Progression Profiling in Context of Omalizumab Asthma Preventention Trial | $4,510 | 0 | 3 |
| Diagnostic Performance of 2nd Generation tTG serological tests in different ethnic populations | $2,304 | 0 | 1 |
| CABAL 1718 The Microbiome, Asthma and Other Atopic Development in the Premature Population | $2,100 | 0 | 8 |
| Multi Allergic Pilot Study | $592.00 | 0 | 1 |
| IDEA Investigating Duliumab's Effect on Asthma by Genotype- CABAL 1922 | $165.00 | 0 | 1 |
| Baked Egg Oral Immunology for Egg Allergic Children | $90.00 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Unknown Provider | — | — | $372,499 | $0 |
| Dr. Yat-Choi Kwong, M.d, M.D | Allergy & Immunology | Los Angeles, CA | $186,838 | $0 |
| Dr. Geoffrey Carlson, Md, MD | Allergy & Immunology | Travis Afb, CA | $103,281 | $0 |
| Brett Coons, Md, MD | Pediatrics | Jb Andrews, MD | $90,988 | $0 |
| Myron Liebhaber, M.d, M.D | Allergy & Immunology | Santa Barbara, CA | $67,401 | $0 |
| Dr. Christopher Webber, M.d, M.D | Allergy | Colorado Springs, CO | $66,595 | $0 |
| Dr. Sofia Szari, M.d, M.D | Pediatrics | Eglin Afb, FL | $65,690 | $0 |
| Dr. Inderpal Randhawa, M.d, M.D | Allergy & Immunology | Long Beach, CA | $52,505 | $0 |
| Dr. Henry Wojtczak, M.d, M.D | Pediatric Pulmonology | Albuquerque, NM | $44,735 | $0 |
| Niti Chokshi, Md, MD | Allergy & Immunology | Houston, TX | $30,856 | $0 |
| Saroj Misra, Do, DO | Family Medicine | Warren, MI | $26,450 | $0 |
| Leroy Graham, Md, MD | Pediatric Pulmonology | Atlanta, GA | $26,143 | $0 |
| Dr. Jay Portnoy, Md, MD | Pediatric Allergy/Immunology | Kansas City, MO | $23,195 | $0 |
| Dr. Leonard Fromer, M.d, M.D | Family Medicine | Los Angeles, CA | $20,912 | $0 |
| Michael Benninger, M.d, M.D | Otolaryngology | Cleveland, OH | $18,178 | $0 |
| Ivor Emanuel, Md, MD | Otolaryngic Allergy | San Francisco, CA | $16,544 | $0 |
| Dr. Randall Brown, Dds, DDS | General Practice | Bay City, MI | $16,508 | $0 |
| Robert Lucas, Md, MD | Obstetrics & Gynecology | Westlake, OH | $15,544 | $0 |
| Dr. Michael Cabana, M.d, M.D | Pediatrics | San Francisco, CA | $15,082 | $0 |
| Allan Luskin, Md, MD | Allergy & Immunology | Madison, WI | $13,645 | $0 |
| Andrew Liu, Md, MD | Pediatric Allergy/Immunology | Denver, CO | $13,424 | $0 |
| Maeve O'connor, Md, MD | Allergy & Immunology | Charlotte, NC | $12,149 | $0 |
| Santiago Martinez, Md, MD | Allergy & Immunology | Orlando, FL | $10,845 | $0 |
| Dr. Priscilla Wong, M.d, M.D | Allergy & Immunology | Roseville, CA | $9,051 | $0 |
| Dr. Matthew Greenhawt, Md, Mba, MD, MBA | Pediatrics | Aurora, CO | $8,284 | $0 |
Top Products
- ImmunoCAP $3.0M
- Phadia 250 $96,837
Associated Products (4)
- ImmunoCAP $3.0M
- Phadia 250 $96,837
- ELIA $61,440
- EliA $60,836
Payment Categories
- Food & Beverage $794,749
- Consulting $546,777
- Travel & Lodging $128,640
- Research $1.0M
About Phadia US Inc.
Phadia US Inc. has made $3.2M in payments to 24,019 healthcare providers, recorded across 37,293 transactions in the CMS Open Payments database. In 2024, the company paid $339,519. The top product by payment volume is ImmunoCAP ($3.0M).
Payments were distributed across 201 medical specialties. The top specialty by payment amount is Allergy & Immunology ($534,776 to 704 doctors).
Payment categories include: Food & Beverage ($794,749), Consulting ($546,777), Research ($1.0M), Travel & Lodging ($128,640).
Phadia US Inc. is associated with 4 products in the CMS Open Payments database, including ImmunoCAP, Phadia 250, and ELIA.